{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Toxicities will be assessed and graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0 terminology. Exact 95% confidence intervals around the toxicity proportions will be calculated to assess the precision of the obtained estimates.","groups":[{"description":"Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\naflibercept: Given IV","id":"OG000","title":"Treatment (Antiangiogenesis Therapy)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants with grade 1 and 2 adverse events","reportingStatus":"POSTED","timeFrame":"up to 6 months","title":"Toxicities","type":"SECONDARY","unitOfMeasure":"Participants"}